Aspire Biopharma Holdings, Inc. (ASBPW) Stock Price & Analysis
Aspire Biopharma Holdings, Inc. (ASBPW) — price $0.0106 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Aspire Biopharma Holdings, Inc. · ASBPW
Aspire Biopharma Holdings, Inc. is a biotechnology company focused on advanced diagnostic solutions and molecular testing. The company develops high-precision assays for disease detection, leveraging research in genetics and biochemistry.
Price as of Nov 19, 2026
Key Statistics
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0106 |
| Change on the day | 0.00% |
| 52-week range | $0.0106 – $0.0437 |
| Shares traded on the day | 44.1K |
Price & events
Other perspectives
Council score for Aspire Biopharma Holdings (ASBPW): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Aspire Biopharma Holdings (ASBPW), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aspire Biopharma Holdings, Inc. (ASBPW) is the company analyzed here. It employs 2 people and is led by Kraig T. Higginson. In Q2 FY2026 it reported revenue of $63,103 and net income of -$1M.
What do the latest results show for Aspire Biopharma Holdings (ASBPW)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $63,103.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $63,103 | -$1M | -$1.22 (diluted) |
| Q1 FY2026 | $28,353 | -$3M | -$2.16 (diluted) |
| Q4 FY2025 | $4,261 | -$5M | -$3.15 (diluted) |
| Q3 FY2025 | $1,941 | -$2M | -$1.49 (diluted) |
What are the financial strengths and risks for Aspire Biopharma Holdings (ASBPW)?
Short answer · as of
The distress and quality screens read Altman Z -3.89 · Piotroski F 5. Trailing ratios: ROA -81.6% · current ratio 7.99 · earnings yield -132.1%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ASBPW in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ASBPW in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Aspire Biopharma Holdings Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the ASBPW research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for ASBPW?
Aspire Biopharma Holdings, Inc. faces several key risks, including limited financial resources, intense competition in the biotechnology industry, and stringent regulatory requirements. The company's small size and limited number of employees pose operational challenges.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 7 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com